Peteryne Miller, MD
Psychiatry · Tulsa, OKNPI 1720026362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.
Across 259 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$670
- Johnson & Johnson$535
- Alkermes, Inc.$388
- Teva Pharmaceuticals USA, Inc.$354
- Otsuka America Pharmaceutical, Inc.$328
- Vanda Pharmaceuticals Inc.$217
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $670 |
| Johnson & Johnson | 36 | $535 |
| Alkermes, Inc. | 24 | $388 |
| Teva Pharmaceuticals USA, Inc. | 18 | $354 |
| Otsuka America Pharmaceutical, Inc. | 22 | $328 |
| Vanda Pharmaceuticals Inc. | 13 | $217 |
| Supernus Pharmaceuticals, Inc. | 6 | $214 |
| Indivior Inc. | 6 | $209 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $190 |
| Sunovion Pharmaceuticals Inc. | 10 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $165 |
| Lundbeck LLC | 8 | $144 |
| Neurocrine Biosciences, Inc. | 5 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $91 |
| Noven Therapeutics, LLC | 4 | $77 |
| Almatica Pharma LLC | 3 | $69 |
| Corium, LLC | 4 | $59 |
| Shire North American Group Inc | 3 | $57 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Harmony Biosciences LLC | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,238 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 22 | $39,425 |
| SpravatoEsketamine Hcl | 13 | $37,759 |
| VraylarCariprazine Hcl | 20 | $28,751 |
| Aripiprazole | 124 | $9,713 |
| TrintellixVortioxetine Hydrobromide | 12 | $9,473 |
| Clozapine | 159 | $8,768 |
| Chlorpromazine Hcl | 41 | $8,033 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 172 | $7,085 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,467 |
| BelsomraSuvorexant | 13 | $5,416 |
| Lurasidone Hcl | 57 | $5,369 |
| Quetiapine Fumarate | 158 | $4,086 |
| Duloxetine Hcl | 86 | $3,607 |
| Fluvoxamine Maleate | 44 | $3,454 |
| Olanzapine | 115 | $2,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $190 | $39,42522 claims |
| Johnson & JohnsonSpravato | $535 | $37,75913 claims |
| AbbVieVraylar | $670 | $28,75120 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $165 | $14,93926 claims |
| Almatica Pharma LLCSertraline Hcl | $69 | $1,049150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Tulsa
- Sarah LandTulsa$287K
- Bradley McClureTulsa$15K
- Katrina CraderTulsa$15K
- Jeffrey CatesTulsa$11K
- Kaitlin CoresTulsa$10K
- Charles van TuylTulsa$9K
- Michael DubriwnyTulsa$8K
- Martin PaulusTulsa$7K
- Joe SpeerTulsa$7K
- Kari YoumanTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.